|
|
|
|
|
| Faffe,D.S.. |
| Asthma is characterized by reversible airway obstruction, airway hyperresponsiveness, and airway inflammation. Although our understanding of its pathophysiological mechanisms continues to evolve, the relative contributions of airway hyperresponsiveness and inflammation are still debated. The first mechanism identified as important for asthma was bronchial hyperresponsiveness. In a second step, asthma was recognized also as an inflammatory disease, with chronic inflammation inducing structural changes or remodeling. However, persistence of airway dysfunction despite inflammatory control is observed in chronic severe asthma of both adults and children. More recently, a potential role for epithelial-mesenchymal communication or transition is emerging, with... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Asthma; Epithelial-mesenchymal unit; Bronchial hyperresponsiveness; Remodeling. |
| Ano: 2008 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2008000900001 |
| |
|
|
| Campos,H.S.; Xisto,D.G.; Oliveira,M.B.G.; Teixeira,I.; Negri,E.M.; Mauad,T.; Carnielli,D.; Lima,L.M.; Barreiro,E.J.; Faffe,D.S.; Zin,W.A.; Lapa e Silva,J.R.; Rocco,P.R.M.. |
| The aim of the present study was to compare the efficacy of a novel phosphodiesterase 4 and 5 inhibitor, LASSBio596, with that of dexamethasone in a murine model of chronic asthma. Lung mechanics (airway resistance, viscoelastic pressure, and static elastance), histology, and airway and lung parenchyma remodeling (quantitative analysis of collagen and elastic fiber) were analyzed. Thirty-three BALB/c mice were randomly assigned to four groups. In the asthma group (N = 9), mice were immunized with 10 µg ovalbumin (OVA, ip) on 7 alternate days, and after day 40 they were challenged with three intratracheal instillations of 20 µg OVA at 3-day intervals. Control mice (N = 8) received saline under the same protocol. In the dexamethasone (N = 8) and LASSBio596... |
| Tipo: Info:eu-repo/semantics/other |
Palavras-chave: Asthma; Lung function; Steroid; Phosphodiesterase inhibitors; BALB/c mice. |
| Ano: 2006 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2006000200016 |
| |
|
|
|
